Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.

ABSTRACT:

Background

Currently, 2 coprimary end points are used by health authorities to determine the effectiveness of therapeutic interventions in patients with Crohn's disease (CD): symptomatic remission (patient-reported outcome assessment) and endoscopic remission (ileocolonoscopy). However, there is lack of accepted biomarkers to facilitate regulatory decision-making in the development of novel therapeutics for the treatment of CD.

Methods

With support from the Helmsley Charitable Trust, Critical Path Institute formed the Crohn's Disease Biomarkers preconsortium (CDBpC) with members from the pharmaceutical industry, academia, and nonprofit organizations to evaluate the CD biomarker landscape. Biomarkers were evaluated based on biological relevance, availability of biomarker assa

SUBMITTER: Porter AC 

PROVIDER: S-EPMC7500523 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature